Rapamycin regulates cholesterol biosynthesis and cytoplasmic ribosomal proteins in hippocampus and temporal lobe of APP/PS1 mouse

Journal of the Neurological Sciences
Xia WangChao Ma

Abstract

As an inhibitor of the immune system and a longevity drug, rapamycin has been suggested as a treatment for Alzheimer's disease, although the underlying mechanisms remain to be clarified. To elucidate the mechanisms, we performed a high-throughput quantitative proteomics analysis and bioinformatics analysis of the changes in the proteome profiles of hippocampus and temporal lobe of wild-type mice, APP/PS1 mice and rapamycin-treated APP/PS1 mice (ProteomeXchange: PXD009540). Morris Water Maze tests were used to evaluate the effectiveness of rapamycin in APP/PS1 treatment and Western blot analysis was used to verify the proteomics data. The results of Morris Water Maze tests indicated that rapamycin improved the spatial learning and memory abilities of APP/PS1 mice. Proteome analysis identified 100 significantly changed (SC) proteins in hippocampus and 260 in temporal lobe in APP/PS1 mice. Among these, 57 proteins in hippocampus and 167 proteins in temporal lobe were rescued by rapamycin. STRING analysis indicated relatively more complicated protein interactions of AD-related rapamycin rescued proteins in temporal lobe. Pathway analysis showed that SC proteins in APP/PS1 mice were mainly enriched in cholesterol biosynthesis pathwa...Continue Reading

Citations

Sep 19, 2020·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Cuiqin HuangDaxiang Lu
Dec 22, 2020·Frontiers in Neuroscience·Antonio MunafòGiuseppina Cantarella
May 19, 2021·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·Hui WangTao Zhang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: RNA Sequencing

RNA sequencing studies have shed light on the genetic and molecular mechanisms related to the pathophysiology of Alzheimer's disease (AD). This feed follows papers using RNA sequencing technologies in Alzheimer's research.